Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
77Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $70.39M | $-43.97M | $-0.50 |
| 2024 | $59.34M | $-65.28M | $-0.89 |
| 2023 | $70.14M | $-76.24M | $-1.12 |
| 2022 | $138.59M | $-33.59M | $-0.51 |
| 2021 | $104.75M | $-21.28M | $-0.33 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $-0.09 per share
Typical surprise +5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.13 vs $-0.14beat
- Thu, May 7$-0.10 vs $-0.11beat
- Wed, Mar 11$0.11 vs $0.01beat
- Thu, Nov 6$-0.22 vs $-0.15miss
- Wed, Aug 13$-0.16 vs $-0.17beat
- Wed, May 14$-0.25 vs $-0.20miss
Estimates and results for CDXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CDXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (4)
- Newszacks.com·1d ago·Positive
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·3d ago·Negative
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
View source ↗ - Newsmarketbeat.com·3d ago·Negative
Codexis Q2 Earnings Call Highlights Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
View source ↗